Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Renese

×

Overview

What is Renese?

Renese is designated generically as polythiazide, and chemically as 2-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide. It is a white crystalline substance, insoluble in water but readily soluble in alkaline solution.

Inert Ingredients: dibasic calcium phosphate; lactose; magnesium stearate; polyethylene glycol; sodium lauryl sulfate; starch; vanillin. The 2 mg tablets also contain: Yellow 6; Yellow 10.



What does Renese look like?



What are the available doses of Renese?

Sorry No records found.

What should I talk to my health care provider before I take Renese?

Sorry No records found

How should I use Renese?

Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure.

Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Therapy should be individualized according to patient response. This therapy should be titrated to gain maximal therapeutic response as well as the minimal dose possible to maintain that therapeutic response. The usual dosage of Renese tablets for diuretic therapy is 1 to 4 mg daily, and for antihypertensive therapy is 2 to 4 mg daily.


What interacts with Renese?

Anuria. Hypersensitivity to this or other sulfonamide derived drugs.



What are the warnings of Renese?



Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy

Thiazides cross the placental barrier and appear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers

Thiazides appear in breast milk. If use of the drug is deemed essential, the patient should stop nursing.


What are the precautions of Renese?

Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance; namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

Hypokalemia may develop with thiazides as with any other potent diuretic, especially with brisk diuresis, when severe cirrhosis is present, or during concomitant use of corticosteroids or ACTH.

Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes mellitus may become manifest during thiazide administration.

Thiazide drugs may increase the responsiveness to tubocurarine.

The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.

Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

If progressive renal impairment becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen, a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy.

Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.


What are the side effects of Renese?

A. GASTROINTESTINAL SYSTEM REACTIONS



















                    B. CENTRAL NERVOUS SYSTEM REACTIONS











                              C. HEMATOLOGIC REACTIONS









                                      D. DERMATOLOGIC—HYPERSENSITIVITY REACTIONS











                                                E. CARDIOVASCULAR REACTION

                                                Orthostatic hypotension may occur and may be aggravated by alcohol, barbiturates or narcotics.

                                                F. OTHER













                                                            Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.


                                                            What should I look out for while using Renese?

                                                            Anuria. Hypersensitivity to this or other sulfonamide derived drugs.

                                                            Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

                                                            Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

                                                            Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

                                                            Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma.

                                                            The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.


                                                            What might happen if I take too much Renese?

                                                            Sorry No Records found


                                                            How should I store and handle Renese?

                                                            RENESE (polythiazide) Tablets are available as:1 mg white, scored tablets in bottles of 100 (NDC 0069-3750-66).2 mg yellow, scored tablets in bottles of 100 (NDC 0069-3760-66).4 mg white, scored tablets in bottles of 100 (NDC 0069-3770-66).RENESE (polythiazide) Tablets are available as:1 mg white, scored tablets in bottles of 100 (NDC 0069-3750-66).2 mg yellow, scored tablets in bottles of 100 (NDC 0069-3760-66).4 mg white, scored tablets in bottles of 100 (NDC 0069-3770-66).RENESE (polythiazide) Tablets are available as:1 mg white, scored tablets in bottles of 100 (NDC 0069-3750-66).2 mg yellow, scored tablets in bottles of 100 (NDC 0069-3760-66).4 mg white, scored tablets in bottles of 100 (NDC 0069-3770-66).RENESE (polythiazide) Tablets are available as:1 mg white, scored tablets in bottles of 100 (NDC 0069-3750-66).2 mg yellow, scored tablets in bottles of 100 (NDC 0069-3760-66).4 mg white, scored tablets in bottles of 100 (NDC 0069-3770-66).


                                                            ×

                                                            Clinical Information

                                                            Chemical Structure

                                                            No Image found
                                                            Clinical Pharmacology

                                                            Non-Clinical Toxicology
                                                            Anuria. Hypersensitivity to this or other sulfonamide derived drugs.

                                                            Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

                                                            Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

                                                            Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

                                                            Sensitivity reactions may occur in patients with a history of allergy or bronchial asthma.

                                                            The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

                                                            Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

                                                            All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance; namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

                                                            Hypokalemia may develop with thiazides as with any other potent diuretic, especially with brisk diuresis, when severe cirrhosis is present, or during concomitant use of corticosteroids or ACTH.

                                                            Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia especially with reference to myocardial activity.

                                                            Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

                                                            Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.

                                                            Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes mellitus may become manifest during thiazide administration.

                                                            Thiazide drugs may increase the responsiveness to tubocurarine.

                                                            The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.

                                                            Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

                                                            If progressive renal impairment becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen, a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy.

                                                            Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

                                                            ×

                                                            Reference

                                                            This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
                                                            "https://dailymed.nlm.nih.gov/dailymed/"

                                                            While we update our database periodically, we cannot guarantee it is always updated to the latest version.

                                                            ×

                                                            Review

                                                            Rate this treatment and share your opinion


                                                            Learn about User Reviews

                                                            Helpful tips to write a good review:

                                                            1. Only share your first hand experience as a consumer or a care giver.
                                                            2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
                                                            3. Fill in the optional information to help other users benefit from your review.

                                                            Reason for Taking This Treatment

                                                            (required)

                                                            Click the stars to rate this treatment

                                                            Effectiveness (required)

                                                            This medication has worked for me.




                                                            Ease of Use (required)

                                                            This medication has been easy for me to use.




                                                            Satisfaction (required)

                                                            Overall, I have been satisfied with my experience.




                                                            Write a brief description of your experience with this treatment:

                                                            2000 characters remaining

                                                            Optional Information

                                                            Help others benefit from your review by filling in the information below.
                                                            I am a:
                                                            Gender:
                                                            ×

                                                            Professional

                                                            Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
                                                            ×

                                                            Tips

                                                            Tips

                                                            ×

                                                            Interactions

                                                            Interactions

                                                            A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).